Daniel Catenacci, MD, Associate Professor of Medicine, is an adult GI medical oncologist, and Director of the gastrointestinal oncology program at the University of Chicago. He serves as the Assistant Director of Translational Research in the Comprehensive Cancer Center. In addition to his clinical practice, Dr. Catenacci is an active basic and clinical researcher, focusing on the treatment of gastroesophageal (esophagus, gastroesophageal junction, and stomach) cancers. His bench-to-bedside translational



research has an overarching goal to validate and improve personalized treatment, immunotherapy, and precision medicine for gastroesophageal cancer and other GI cancers. A major focus of his research is on the quantification of tumor genetic molecular heterogeneity both between individuals with gastroesophageal cancer, but importantly also within a given individual within one tumor site, and from one tumor site to another, and how this impacts personalized targeted therapeutic approaches. Additionally, Dr. Catenacci designs and executes novel clinical trials to implement treatment strategies based on these laboratory and clinical discoveries. Dr. Catenacci serves as Associate Editor for the Journal of American Medical Association Network Open (JAMA Netw Open) and is on the editorial board of the Journal of Clinical Oncology Precision Oncology (J Clin Oncol PO).

This Symposium has been made possible by the generosity and love of Katy Rady and Paul Rady, the sister and close friend of Paul R. O'Hara II.

Paulie, as he was known by his family and friends, was diagnosed with esophageal adenocarcinoma in July, 2013. He initially received appropriate treatment at the University of Michigan NCI Comprehensive Cancer Center.

Paulie did well at first but the cancer persisted. In January, 2015, Paulie's case was reviewed and Paulie was subsequently seen by the Multidisciplinary Esophagogastric Cancer Team. Dr. Madeleine and the team recommended a course of chemotherapy. Paulie received his treatment in Michigan.

Unfortunately, Paulie struggled with side effects from the chemotherapy even with a change in chemotherapy treatment. Nutrition, pain and cancer progression were his constant companions. In August, 2015 he was able to attend a reunion of college friends in Michigan at his newly built home on Lake Michigan. In September, 2015 Paulie decided to end chemotherapy treatment and enter comfort care. He passed away on October 11, 2015.

Katy and Paul Rady decided to establish the Paul R. O'Hara, II Endowed Chair in Esophagogastric Cancer in April 2017 to honor Paulie's memory. This gift generates funding for cutting edge research, this symposium with more plans for the future.

— W E L C O M E ——

The University of Colorado Cancer Center and UCHealth are pleased to present the Third Annual Paul R. O'Hara II Esophagogastric Cancer Symposium to heighten community and professional awareness about esophagogastric cancer.

> Saturday, April 19, 2019 8:00 AM—2:00 PM

University of Colorado Anschutz Medical Campus

Third annual Paul R. O'Hara II Esophagogastric Cancer Symposium			10:05-10:20 AM	"The Role cfDNA as a Prognostic Marker for Gastroesophageal Cancers"	Sunnie Kim, MD, Assistant Professor of Medical Oncology
Saturday, April 18, 2020 Objectives			10:20-10:35 AM	"Biomarkers in Esophageal Cancer"	Akshay Chauhan, MD, Assistant Professor of Surgery
 Educate patient, caregivers, providers about screening, care and outcomes for esophagogastric cancer patients Heighten community and professional awareness about esophagogastric cancer 			10:35-10:50 AM	Update on Screening for Esophagogastric cancers	Sachin Wani, MD, Associate Professor of Gastroenterology
Create support groups, network for patients and caregivers Agenda			10:50-11:35 AM	Keynote Address: "Cell free DNA in Prognosis of Esopahgogastric cancer…"	Daniel Catenacci, MD, Associate Professor, Department of Medicine, Section of Hematology & Oncology
8:00-9:00 AM	Check in and Breakfast Buffet		11:35-11:50 AM	Lunch and go to Breakout Session I	
8:30-8:35 AM	Welcome	Madeleine Kane, MD PhD, Professor of Medical Oncology	11:50 AM-12:20 PM 12:25-12:55 PM	Breakout Session I Breakout Session II	
8:35-8:55 AM	Welcome and Update on Esophagogastric Cancer	Richard Schulick, MD, Professor and Chair of Surgery, University of Colorado cancer Center	1:00-1:40 PM	Developing advocacy for esophagogastric cancers	
8:55-9:10 AM	Remarks	Director Katy and Paul Rady	1:40-2:00 PM	Wrap up	
9:10-9:30 AM	Therapy for Esophagogastric Adenocarcinoma: Phase II Study of induction FLOT followed by CROSS Chemoradiation"	Jeffrey Olsen, MD, Assistant Professor of Radiation Oncology	 Choose two from these three breakout sessions: "Medical and Psychosocial Support During Esophagogastric Cancer Treatment"Lindsey Davis, MD, Assistant Professor of Medical Oncology and Emily Cox-Martin, PhD, Assistant Professor of Medical Oncology/Clinical Psychology "Life after Treatment for Esophageal/Gastric Cancers"Valaree Williams, RD, and Carlin Callaway, NP 		
9:30-9:50 AM	"Organoids in Esophagogastric Cancer	Peter Dempsey, MD, Professor of Pediatrics	 "Chemotherapyhow is it developed?" Alexis Leal, MD, Assistant Professor of Medical Oncology, and Kimmie Sun, MD, Assistant Professor of Medical Oncology 		